Abstract:Abstract Background Crohn’s disease (CD) is an inflammatory bowel disease with chronic course and exacerbations. Diagnosis and follow-up are based on clinical activity, biomarkers, ileocolonoscopy and imaging techniques. Intestinal ultrasound (IUS) has been shown to have high sensitivity and specificity analyzing inflammatory activity in CD. The aim of our study is to correlate IUS parameters with clinical activity and biomarkers in CD. Methods Retrospective, observational, single-center study was designed. Adult patients with CD who underwent IUS between September 2020 and May 2021 were included. Exclusion criteria was exclusive colonic involvement. Examination was done by ultrasound machine (Hitachi Ascendus) with low frequency curved-array (1–5 MHz) and high-frequency linear-array (5–13 MHz) transducers. Examination assessed bowel wall thickness, mesenteric fat hypertrophy, lymph nodes, hyperemia on color Doppler flow measured as Limberg index and length of affected segment (cm). Clinical activity score for CD was assessed by Harvey Bradshaw index (HBI). Biomarkers parameters studied were C-reactive protein (CRP) and faecal calprotectin (FC). Results are shown as percentages, median and interquartile range (IQR). Data were analysed using Spearman′s correlation analysis Results 121 patients were included (median age 45.6 years (IQR 33.4 – 59.6), 56.2% female). 78.5% had ileal disease and 21.5% ileocolonic involvement. At the time of IUS 17.4% of patients were not taking any maintenance treatment, 13.2% were on azathioprine, 48.8% on anti-TNF (61% adalimumab; 39% infliximab) and 8.3% on ustekinumab. 85.1% patients had HBI <6, 14.1% had moderate activity. Median CRP level was 0.334 mg/dl (IQR 0.06–1.12), FC was 141 μg/g (IQR 35–386). Median wall thickening was 4.7 mm (range 4.1–5.6), 68.6% of patients had mesenteric fat hypertrophy and 73.55% had lymph nodes. Limberg index was 0 in 20.7%, 1 in 23.1%, 2 in 37.2% and 3 in 19% of patients. IUS determined treatment modification in 60.3% of cases: 19% started biological therapy, 15.7% changed biological target, 14.9% underwent intensification or reinduction of biological treatment, in 1.7%, treatment reduction was decided. The Spearman′s correlation between IUS parameters, clinical and biochemical markers is presented in Table 1. IUS parameters were significantly associated with faecal calprotectin and CRP level, specially Limberg Index and faecal calprotectin (r=0.56, p<0.05) and Limberg Index and CRP level (r= 0.38, p<0.05) (Figure 1 and 2). No correlation was observed between HBI and IUS parameters. Conclusion Through this study, significant correlation between IUS and biomarkers was observed in CD. IUS has been shown to be useful for monitoring CD activity in order to optimize patients′ treatment.

P042 Significant correlation between intestinal ultrasound and magnetic resonance enterography for assessing disease activity and complications in Crohn’s disease

P405 Intestinal ultrasound measures are highly correlated with small bowel Lewis score among patients with active Crohn’s disease

P601 Intestinal ultrasound correlates with clinical, biochemical, endoscopic and histologic biomarkers in patients with Ulcerative Colitis: a cross-sectional study

P075 Early intestinal ultrasound non-response is a prediction tool of complicated disease outcome in Crohn’s disease patients treated with infliximab

DOP15 Intestinal ultrasound correlates with colonoscopy and biomarkers, and can be used in a tight monitoring approach to assess response to therapy in Crohn's disease: a multicentre prospective study

P691 Intestinal ultrasonography accuracy in the evaluation of patients with moderate to severe ulcerative colitis starting infliximab therapy

The prospective study of intestinal ultrasonography in the diagnosis and assessment of IBD activity

Magnetic resonance enterography and intestinal ultrasound for the assessment and monitoring of Crohn’s disease

P310 Intestinal ultrasound as a tool to assess treatment response in patients with Inflammatory Bowel Diseases

Contrast-enhanced Ultrasound in the Assessment of Crohn’s Disease Activity: Comparison with Computed Tomography Enterography

P248 The diagnostic accuracy of Intestinal ultrasound for assessing disease activity in the proximal ileum and jejunum in children with Crohn’s disease: Preliminary results of a prospective study

Reliability of intestinal ultrasound for evaluating Crohn's disease activity using point-of-care and central reading

Conventional Ultrasound and Contrast-Enhanced Ultrasound in Evaluating the Severity of Crohn'S Disease

P400 Experience with the use of intestinal ultrasound and application of the Milan Ultrasound Criteria in Colombian patients with ulcerative colitis

P243 Relationship between intestinal ultrasound, fecal calprotectin and Harvey-Bradshaw Index in the assessment of infllamatory activity in Cronh′s Disease

Intestinal Ultrasound Early on in Treatment Follow-up Predicts Endoscopic Response to Anti-TNFα Treatment in Crohn’s Disease

P484 Intestinal Ultrasound Can Detect Active Inflammation In Inflammatory Bowel Disease Patients Despite Combined Clinical And Biomarker Remission

Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests

Intestinal wall thickness detected by multidetector spiral computed tomography enterography predicts the disease severity of Crohn's disease.

Non-invasive evaluation of mucosal healing by intestinal ultrasound or fecal calprotectin is efficient in Crohn's disease: A cross-sectional study

IDDF2019-ABS-0186 Correlation Between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease